Presence & RecognitionEvent: August 31, 2026
OneChain Immunotherapeutics is hosting a talk on Tuesday at 3pm featuring the latest data from the next-generation lentiviral in vivo CAR-T platform.
Published
Signal category
Presence & Recognition
Quote
“Come see my talk with the latest data from our next-generation lentiviral in vivo CAR-T platform on Tuesday at 3pm”
— Stefanos Theoharis|OneChain Immunotherapeutics team
Company
OneChain Immunotherapeutics
Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.
- Industry
- Biotechnology Research
- Location
- BARCELONA, ES
- Company size
- 21 employees
OneChain Immunotherapeutics is a spin-off Company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.
Founded 2020